Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort
Clinical Infectious Diseases · 28.10.2026 · 83 (4) · 596-600
DOI: 10.1093/cid/ciag316 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 15.05.2026. Verfasst von Aniruddha Hazra und 24 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Diseases and Global Health, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents, Quinolones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Lenacapavir preexposure prophylaxis (PrEP) implementation across 17 US sites ( ampa#thinsp;= 501) was characterized by delays in initiation driven by payer processes. Early nonpersistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable barriers to early persistence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Infectious Diseases and Global Health, University of Chicago, Chicago, Illinois, USA.
- Howard Brown Health, Chicago, Illinois, USA.
- Rhode Island Public Health Institute, Providence, Rhode Island, USA.
- Department of Infectious Diseases, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana, USA.
- LSU-CrescentCare Sexual Health Center, New Orleans, Louisiana, USA.
- Jefferson Einstein Philadelphia, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Aniruddha Hazra, Meredith Clement, Joseph Cherabie, Rona Vail
Zitieren
APA
Hazra, A., Chan, P. A., Clement, M., Kaperak, C. J., Safa, H., Havens, J. P., Springer, S. A., Blumenthal, J., Spinelli, M., Doblecki-Lewis, S., Multani, A., Gipson, J., Cherabie, J., Vail, R., Sukumaran, S., Cannon, C. A., Lillis, R., Butler, I., Turner, C., …, & Patel, R. R. (2026). Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort. Clinical Infectious Diseases, 83(4), 596-600. https://doi.org/10.1093/cid/ciag316
Vancouver
Hazra A, Chan PA, Clement M, Kaperak CJ, Safa H, Havens JP, et al. Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort. Clinical Infectious Diseases. 2026;83(4):596-600. doi:10.1093/cid/ciag316
BibTeX
@article{Hazra2026,
author = {Hazra, Aniruddha and Chan, Philip A and Clement, Meredith and Kaperak, Christopher J and Safa, Hussein and Havens, Joshua P and Springer, Sandra A and Blumenthal, Jill and Spinelli, Matthew and Doblecki-Lewis, Susanne and Multani, Ami and Gipson, June and Cherabie, Joseph and Vail, Rona and Sukumaran, Stephen and Cannon, Chase A and Lillis, Rebecca and Butler, Isolde and Turner, Christian and Taraschi, Ellen and Narcisse-Cempini, Gilianne and Kunzmann, Leah and Smith, Romini and Halbur, Drew and Patel, Rupa R},
title = {Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {83},
number = {4},
pages = {596--600},
doi = {10.1093/cid/ciag316}
}
EUVIMED